4.08
-0.10 (-2.39%)
| Previous Close | 4.18 |
| Open | 4.17 |
| Volume | 451,708 |
| Avg. Volume (3M) | 606,410 |
| Market Cap | 332,021,856 |
| Price / Sales | 2.93 |
| Price / Book | 4.29 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 |
| Profit Margin | -149.47% |
| Operating Margin (TTM) | -271.59% |
| Diluted EPS (TTM) | -0.980 |
| Quarterly Revenue Growth (YOY) | -55.80% |
| Total Debt/Equity (MRQ) | 119.88% |
| Current Ratio (MRQ) | 3.72 |
| Operating Cash Flow (TTM) | -55.42 M |
| Levered Free Cash Flow (TTM) | -31.16 M |
| Return on Assets (TTM) | -30.06% |
| Return on Equity (TTM) | -115.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Codexis, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -5.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -4.0 |
| Average | -2.75 |
|
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.49% |
| % Held by Institutions | 83.39% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | - | 1.71 | -514,341 | -871,060 |
| Aggregate Net Quantity | -514,341 | |||
| Aggregate Net Value ($) | -871,060 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 1.71 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 01 Dec 2025 | Sell (-) | 253,533 | 1.65 | 418,329 | |
| OPALEYE MANAGEMENT INC. | 28 Nov 2025 | Sell (-) | 107,490 | 1.73 | 185,958 | |
| OPALEYE MANAGEMENT INC. | 26 Nov 2025 | Sell (-) | 153,318 | 1.74 | 266,773 |
| Date | Type | Details |
|---|---|---|
| 10 Nov 2025 | Announcement | Codexis Announces Signing of Lease for GMP Manufacturing Facility |
| 06 Nov 2025 | Announcement | Codexis Reports Third Quarter 2025 Financial Results |
| 29 Oct 2025 | Announcement | Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing |
| 23 Oct 2025 | Announcement | Codexis to Report Third Quarter 2025 Financial Results on November 6 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |